Table 1.

Serum HYA Levels in Subgroups of Myeloma Patients

N % Serum Hyaluronan Level Total %
0-9 μg/L 10-120 μg/L >120 μg/L
N % N % N %
Stage  
 I  34 9  0  0  32  94  2  6  100  
 II  130 34  6  5  106  82  18  14  100  
 III 222  57  14  6  177  80  31  14  100 
 Total  386  100  
M-comp Ig class* 
 IgA  82 21  10  12  67  82  5  6  100  
 IgG 224  59  9  4  186  83  29  13  100 
 BJ 76  20  1  1  59  78  16  21 100  
 Total  382  100 
N % Serum Hyaluronan Level Total %
0-9 μg/L 10-120 μg/L >120 μg/L
N % N % N %
Stage  
 I  34 9  0  0  32  94  2  6  100  
 II  130 34  6  5  106  82  18  14  100  
 III 222  57  14  6  177  80  31  14  100 
 Total  386  100  
M-comp Ig class* 
 IgA  82 21  10  12  67  82  5  6  100  
 IgG 224  59  9  4  186  83  29  13  100 
 BJ 76  20  1  1  59  78  16  21 100  
 Total  382  100 

Number and percentage of myeloma patients in different disease stages (upper part) and with different M-component Ig classes (lower part) are given to the left. To the right individuals in the various stages (upper part) and with various M-component Ig classes (lower part) are separated according to abnormally low, intermediate, and high serum HYA levels.

*

Three cases with IgD and one nonsecretory case are excluded.

Bence Jones protein.

Close Modal

or Create an Account

Close Modal
Close Modal